Research programme: Hedgehog cell signaling pathway inhibitors - GliGene AB
Latest Information Update: 16 Jul 2016
At a glance
- Originator GliGene
- Mechanism of Action Hedgehog cell-signalling pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in Sweden
- 14 Feb 2012 Early research in Solid tumours in Sweden (unspecified route)